Johnson & Johnson's

Johnson & Johnson's plan for bankruptcy to end talc cancer claims rejected

US Bankruptcy Judge Christopher Lopez on Monday dismissed the bankruptcy of a small J&J unit called Red River Talc following a two-week trial in Houston

Johnson & Johnson increases US investment to over $55 bn over next 4 yrs

Johnson and Johnson, US healthcare's leading, most comprehensive innovation powerhouse, announced on Friday that it will invest more than USD 55 billion in manufacturing, research and development, and technology in the United States over the next four years.According to Johnson and Johnson's statement, this represents a 25 per cent increase in investment compared to the previous four years and builds upon the Company's already elevated US investment levels resulting from the passage of the 2017 Tax Cuts & Jobs Act."Today's announcements accelerate our nearly 140-year legacy as an American innovation engine tackling the world's toughest healthcare challenges," said Joaquin Duato, Chairman and Chief Executive Officer of Johnson and Johnson. "Our increased US investment begins with the ground-breaking of a high-tech facility in North Carolina that will not only add US-based jobs but manufacture cutting-edge medicines to treat patients in America and around the world."In addition to

US FDA declines to approve injection form of J&J's lung cancer drug

The FDA's so-called complete response letter was related to observations as part of a standard pre-approval inspection at a manufacturing facility

J&J gets $260 million talc verdict overturned in Oregon, new trial ordered

J&J is facing claims by more than 62,000 plaintiffs that its baby powder and other talc products were contaminated with asbestos and caused cancer

US FDA expands J&J's psoriasis drug Tremfya for inflammatory bowel disease

Drugmakers such as AbbVie, Eli Lilly and J&J are hustling for a share in an already-crowded, multi-billion market for treatments for inflammatory bowel diseases

J&J talc users want cancer checks for women even if it cost billions

The suit is the latest salvo in the ongoing legal battle between J&J and former talc users, who allege the world's largest maker of health-care products hid the cancer risks of its iconic baby powder

Rare blood clots from J&J and AstraZeneca Covid shots linked to genetics

Out of more than 18 million people who received the single-dose J&J vaccine, 60 cases of the clotting disorder were reported and nine people died, according to the Yale School of Medicine

Johnson & Johnson to buy equipment maker Shockwave Medical for $12.5 bn

Under the deal, J&J would pay $335 per share in cash for the medical device maker. The offer price implies a 4.7% premium to Shockwave's last close of $319.99 on Thursday

J&J's immune disorder drug succeeds in mid and late-stage studies

The drug, nipocalimab, significantly reduced symptoms of generalized myasthenia gravis (gMG) in a late-stage study, and in a mid-stage study helped reduce Sjogren's disease severity, J&J said

New Jersey court tosses $223.8 mn verdict against J&J in talc cancer case

J&J is separately suing one of those experts, Jacqueline Moline, over a study she co-authored in 2019. That study was not at issue in Tuesday's decision

J&J's proposed $8.9 bn talc lawsuits settlement faces US bankruptcy test

US bankruptcy law typically shields debtors from lawsuits while they reorganize in bankruptcy

J&J wins pause of baby powder trials, must face new suits, says judge

US Bankruptcy Judge Michael Kaplan said Thursday the company won't have to go to trial over any talc lawsuits for at least 60 days, but new lawsuits can be filed

J&J talc unit second bankruptcy must be dismissed, victims' lawyers say

The attorneys, in the filing, denounced J&J's move to refile its subsidiary LTL Management for bankruptcy, which relies on a controversial legal maneuver, just two hours after first case was dismissed

J&J proposes paying $8.9 bn to settle baby talcum powder lawsuits

Johnson & Johnson is earmarking nearly USD 9 billion to cover allegations that its baby power containing talc caused cancer, more than quadrupling the amount that the company had previously set aside to pay for its potential liability. Under a proposal announced Tuesday, a J&J subsidiary will re-file for Chapter 11 bankruptcy protection and seek court approval for a plan that would result in one of the largest product-liability settlements in U.S. history. The USD 8.9 billion that J&J would transfer to the subsidiary, LTL Management, would be payable over the next 25 years. The amount is up from the USD 2 billion that the New Brunswick, New Jersey, company set aside in October 2021. The revised amount is being backed by more than 60,000 parties that have filed lawsuits alleging harm from J&J talcum powder, according to the company. J&J isn't admitting any wrongdoing as part of the proposed settlement, a point that company executive emphasised in a Tuesday statement

Johnson & Johnson's dengue antiviral drug shows positive results

Around November, the ICMR sought the drug regulator's nod for phase-3 trials of a vaccine candidate it developed with drugmakers SII and Panacea Biotec

Bombay HC orders testing of J&J baby powder, allows firm to manufacture

The Bombay High Court on Wednesday ordered for fresh testing of Johnson & Johnson baby powder samples and permitted the company to manufacture the product but to not sell it, as per the Maharashtra government order. The company had filed a petition challenging two orders of the state government- one dated September 15 cancelling the license and the second dated September 20 ordering to immediately stop manufacturing and sale of the company's baby powder product. The orders were passed by the joint commissioner and licensing authority of the state Food and Drug Administration (FDA). The government based its orders on the report of the Central Drug Laboratory in Kolkata, which found the powder containing higher pH level than prescribed. A division bench of Justices S V Gangapurwala and S G Dige on Wednesday directed the FDA to collect fresh samples from the company's factory in Mulund area of Mumbai within three days. The sample would then be sent to three laboratories - two ...

Hetero acquires J&J's Telangana plant, to invest Rs 600 crore more

Pharmaceuticals firm Hetero on Monday said it has acquired the manufacturing plant of Johnson & Johnson at Penjerla in Telangana and will invest additional Rs 600 crore on its upgradation. According to sources, the company has acquired the plant for Rs 130 crore. The facility is spread across 55.27 acres and will be Hetero's flagship sterile pharmaceutical and biologics manufacturing unit and will generate 2,000 new jobs, the company said in a statement. "We are committed to an investment upwards of USD 75 million, (approximately Rs 600 crore) to upgrade and enhance existing facilities at the site and expand manufacturing of our global biologics and sterile pharmaceutical products," Hetero Managing Director Vamsi Krishna Bandi said. Hetero said the brownfield manufacturing facility together with land, plant and machinery has been acquired from Johnson & Johnson Pvt Ltd in a slump sale without disclosing the financial details. PwC acted as the exclusive financial advisor to the

Johnson and Johnson: Why talc-based powder will stop their sales in 2023?

After 38,000 serious allegations, Johnson and Johnson's talc-based baby powder will stop international sales from 2023. The product has already been discontinued in the US and Canada

Biological E gets WHO nod to be addl facility for production of J&J vaccine

Biological E has received the WHO nod to be an additional facility for production of Johnson & Johnson COVID-19 vaccine. "Congratulations to @biological_e on its @WHO approval as an additional manufacturing site for the Janssen/Johnson & Johnson COVID-19 vaccine! Great progress for the Quad Vaccine and #USIndiaHealth partnerships through U.S. technical support and @DFCgov financing," the US embassy in India said in a tweet on Wednesday. India's first indigenously developed RBD protein subunit vaccine, Biological E's Corbevax, is currently being used to inoculate children in the age group of 12 to 14 years. The Drugs Controller General of India (DCGI) recently approved Corbevax as a precaution dose for those aged 18 and above.

J&J says still in talks with Indian govt on Covid-19 vaccine

India had, in May, scrapped local trials for 'well-established' foreign coronavirus vaccines as it tried to hasten vaccination rollouts to fight a second wave of infections.